|View printer-friendly version|
|Medtronic Introduces Updated iPro(TM)2 myLog App with FoodPrint(TM) Report Enhancing Diagnostic CGM for People with Diabetes|
(GLOBE NEWSWIRE via COMTEX) --
Expanded Relationship with Nutrino's FoodPrint Will Leverage Food Data Analytics Across Diabetes Portfolio
DUBLIN - June 19, 2018 - Medtronic (NYSE:MDT), the global leader in medical technology, today announced the availability of the updated iPro(TM)2 myLog app with FoodPrint(TM) Report. The iPro2 myLog app offers a simple way for clinics to import patients' logged data during their professional iPro2 continuous glucose monitoring (CGM) evaluation. With the addition of the FoodPrint report, patients' meals are graded based on their body's unique glucose reaction, making it easy for them to understand the link between meals and glucose variability.
The iPro2 myLog app, now powered by Nutrino, a leading AI (artificial intelligence) personalized nutrition analysis platform, is used during a professional iPro2 CGM evaluation for the patient to log their blood glucose (BGs), food and activity. Meal logging is easy; patients simply take a photo of each meal and snack. Upon completion of the 6-day CGM evaluation, the information from the app is synchronized with sensor glucose data and creates two unique reports - the Pattern Snapshot report and the new FoodPrint report. The Pattern Snapshot report shows critical glucose information such as time in target glucose range, identified patterns of glucose variability, and a clear graph of the full glucose tracing. The FoodPrint report shows pictures of meals taken for breakfast, lunch and dinner and scores (A, B, C, D or F) each meal based on the body's glucose reaction. Together these reports help the physician and the patient work together to develop a personalized therapy and treatment plan.
"By making it easier to communicate relevant, personal insights about food's impact on diabetes, Medtronic arms physicians and diabetes educators with a powerful coaching tool that will help drive positive behavior change," said Sheri Dodd, vice president and general manager for Non-Intensive Diabetes Therapies (NDT). "Our partnership with Nutrino to infuse more detail about diet's impact on glucose furthers our goal to make glucose a vital sign in the treatment of diabetes."
Recognizing the important and intertwined impact that food has on diabetes, Medtronic has expanded its partnership with Nutrino, a leader in food data analytics with its flagship FoodPrint technology. Following two years of successful partnering and results, this expanded relationship will embed food data and FoodPrint insights across all the Diabetes Group businesses.
"We are proud to partner with Medtronic to deliver insights through the FoodPrint report, which can help people across the diabetes spectrum to better understand their responses to particular foods," said Yael Glassman, CEO of Nutrino Health. "We're confident that the addition of FoodPrint into the iPro2 professional CGM evaluation will have a positive impact for individuals living with type 2 diabetes."
About Diabetes Group at Medtronic
All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via Globenewswire